Differences in Cardiac Function, Infarct Size and FGF21 autocrine secretory pattern in lean and obese hearts treated with FGF21.

LVDP (mmHg) and left ventricular contractility (dp/dt) in obese control (saline treated) groups [Fig. 7A1], obese (FGF21 treated) groups [Fig. 7A2] and lean (FGF21 treated) groups [Fig. 7A3]; following global ischemia and reperfusion. Graphical representation of the infarcted area (%) in obese control, obese and lean FGF21 (100 nM) treated rat hearts following global ischemia and reperfusion [Fig. 7B]. Graphical representation of FGF21 levels in obese and lean FGF21 (100nM) pre-treated rat heart coronary effluents following global ischemia and reperfusion [Fig 6C]. Data shown are means ± SEM of triplicates. The values represented are relative to basal. ***P #P